{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:35:41Z","timestamp":1781134541842,"version":"3.54.1"},"reference-count":90,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Ventricular arrhythmias still represent an important cause of morbidity and mortality, especially in patients with heart failure and reduced left ventricular ejection fraction. Amiodarone is a Class III Vaughan-Williams anti-arrhythmic drug widely used in ventricular arrhythmias for its efficacy and low pro-arrhythmogenic effect. On the other hand, a significant limitation in its use is represented by toxicity. In this review, the pharmacology of the drug is discussed to provide the mechanistic basis for its clinical use. Moreover, all the latest evidence on its role in different clinical settings is provided, including the prevention of sudden cardiac death, implanted cardioverter defibrillators, ischemic and non-ischemic cardiomyopathies. A special focus is placed on everyday clinical practice learning points, such as dosage, indications, and contraindications from the latest guidelines.<\/jats:p>","DOI":"10.31083\/j.rcm2204143","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T02:04:36Z","timestamp":1640225076000},"source":"Crossref","is-referenced-by-count":21,"title":["Amiodarone in ventricular arrhythmias: still a valuable resource?"],"prefix":"10.31083","volume":"22","author":[{"given":"Luigi","family":"Pannone","sequence":"first","affiliation":[{"name":"Vita-Salute University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"D\u2019Angelo","sequence":"first","affiliation":[{"name":"Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Gulletta","sequence":"first","affiliation":[{"name":"Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Falasconi","sequence":"first","affiliation":[{"name":"Vita-Salute University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Brugliera","sequence":"first","affiliation":[{"name":"Department of Rehabilitation and Functional Recovery, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Frontera","sequence":"first","affiliation":[{"name":"Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cianfanelli","sequence":"first","affiliation":[{"name":"Vita-Salute University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Baldetti","sequence":"first","affiliation":[{"name":"Cardiac Intensive Care Unit, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ossola","sequence":"first","affiliation":[{"name":"Vita-Salute University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Melillo","sequence":"first","affiliation":[{"name":"Vita-Salute University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"De    \n\t\t\t\t\t\tBlasi","sequence":"first","affiliation":[{"name":"Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Malatino","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95131 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Landoni","sequence":"first","affiliation":[{"name":"Vita-Salute University, 20132 Milan, Italy"},{"name":"Anesthesia Intensive Care, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Margonato","sequence":"first","affiliation":[{"name":"Vita-Salute University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Della    \n\t\t\t\t\t\tBella","sequence":"first","affiliation":[{"name":"Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Zacchetti","sequence":"first","affiliation":[{"name":"Vita-Salute University, 20132 Milan, Italy"},{"name":"Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Vergara","sequence":"first","affiliation":[{"name":"Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Vassallo P, Trohman RG. Prescribing Amiodarone. Journal of the American Medical Association. 2007; 298: 1312.","DOI":"10.1001\/jama.298.11.1312"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Al-Khatib SM, LaPointe NMA, Curtis LH, Kramer JM, Swann J, Honig P, et al. Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. The American Journal of Cardiology. 2003; 91: 91\u201394.","DOI":"10.1016\/S0002-9149(02)03008-4"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hayward C, Patel HC, Patel K, Di Mario C, Lyon AR, Ahsan SY, et al. The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998\u20132014. European Heart Journal - Cardiovascular Pharmacotherapy. 2016; 2: 90\u201394.","DOI":"10.1093\/ehjcvp\/pvv048"},{"key":"ref4","unstructured":"Bertholet M, Hastir F, Renier J, Demoulin JC, Kulbertus HE. The value of amiodarone for the treatment of unstable angina. Acta Cardiologica. 1983; 38: 503\u2013511."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: Experimental and clinical observation relative to serum and tissue drug concentrations. American Heart Journal. 1984; 108: 890\u2013898.","DOI":"10.1016\/0002-8703(84)90451-4"},{"key":"ref6","unstructured":"The \u201csicilian gambit\u201d: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. European Heart Journal. 1991; 12: 1112\u20131131."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Kalbfleisch SJ, Williamson B, Man KC, Vorperian V, Hummel JD, Hasse C, et al. Prospective, randomized comparison of conventional and high dose loading regimens of amiodarone in the treatment of ventricular tachycardia. Journal of the American College of Cardiology. 1993; 22: 1723\u20131729.","DOI":"10.1016\/0735-1097(93)90603-X"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Elsherbiny ME, El-Kadi AOS, Brocks DR. The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. Journal of Pharmacy and Pharmaceutical Sciences. 2008; 11: 147\u2013159.","DOI":"10.18433\/J3SG66"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. Journal of Clinical Pharmacology. 1991; 31: 1061\u20131069.","DOI":"10.1002\/j.1552-4604.1991.tb03673.x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links T, Vanderpump M. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. European Thyroid Journal. 2018; 7: 55\u201366.","DOI":"10.1159\/000486957"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. The American Journal of Medicine. 1991; 91: 507\u2013511.","DOI":"10.1016\/0002-9343(91)90187-3"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Jessurun GAJ, Boersma WG, Crijns HJGM. Amiodarone-Induced Pulmonary Toxicity. Drug Safety. 1998; 18: 339\u2013344.","DOI":"10.2165\/00002018-199818050-00003"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kennedy JI, Myers JL, Plumb VJ, Fulmer JD. Amiodarone Pulmonary Toxicity. Clinical, radiologic, and pathologic correlations Archives of Internal Medicine. 1987; 147: 50\u201355.","DOI":"10.1001\/archinte.147.1.50"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kojima S, Kojima S, Ueno H, Takeya M, Ogawa H. Increased Density of the Liver and Amiodarone-Associated Phospholipidosis. Cardiology Research and Practice. 2009; 2009: 1\u20133.","DOI":"10.4061\/2009\/598940"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gayam V, Khalid M, Dahal S, Garlapati P, Gill A, Alex R, et al. Fatal Acute Liver Failure with Intravenous Amiodarone: a Case Report and Literature Review. Gastroenterology Research. 2018; 11: 62\u201363.","DOI":"10.14740\/gr911w"},{"key":"ref16","unstructured":"Jones DB, Mullick FG, Hoofnagle JH, Baranski B. Reye\u2019s syndrome-like illness in a patient receiving amiodarone. The American Journal of Gastroenterology. 1988; 83: 967\u2013969."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Morse RM, Valenzuela GA, Greenwald TP, Eulie PJ, Wesley RC, McCallum RW. Amiodarone-induced liver toxicity. Annals of Internal Medicine. 1988; 109: 838\u2013840.","DOI":"10.7326\/0003-4819-109-10-838"},{"key":"ref18","unstructured":"Kaplan LJ, Cappaert WE. Amiodarone-induced corneal deposits. Annals of ophthalmology. 1984; 16: 762\u2013766."},{"key":"ref19","unstructured":"Harris CR. The toxicology handbook for clinicians. 3rd Edition. Mosby Elsevier: Netherlands. 2006"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sivaram CA, Beckman KJ. Amiodarone-Induced Skin Discoloration. New England Journal of Medicine. 1997; 337: 1813\u20131813.","DOI":"10.1056\/NEJM199712183372505"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Annals of Internal Medicine. 1994; 121: 529\u2013535.","DOI":"10.7326\/0003-4819-121-7-199410010-00009"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. The New England Journal of Medicine. 2004; 350: 1013\u20131022.","DOI":"10.1056\/NEJMra032426"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Pollak PT, Sharma AD, Carruthers SG. Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. The American Journal of Cardiology. 1989; 64: 1138\u20131143.","DOI":"10.1016\/0002-9149(89)90866-7"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003; 89: 1363\u20131372.","DOI":"10.1136\/heart.89.11.1363"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. Journal of Cardiovascular Electrophysiology. 1995; 6: 920\u2013936.","DOI":"10.1111\/j.1540-8167.1995.tb00368.x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SHM, Leunissen JDM, van der Hulst FF, et al. Chronic Amiodarone Evokes no Torsade de Pointes Arrhythmias despite QT Lengthening in an Animal Model of Acquired Long-QT Syndrome. Circulation. 2001; 104: 2722\u20132727.","DOI":"10.1161\/hc4701.099579"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Meierhenrich R, Helguera ME, Kidwell GA, Tebbe U. Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome. International Journal of Cardiology. 1997; 60: 289\u2013294.","DOI":"10.1016\/S0167-5273(97)00073-9"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Sicouri S, Moro S, Litovsky S, Elizari MV, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. Journal of Cardiovascular Electrophysiology. 1997; 8: 1269\u20131279.","DOI":"10.1111\/j.1540-8167.1997.tb01018.x"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991; 84: 1136\u20131144.","DOI":"10.1161\/01.CIR.84.3.1136"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, Holroyde MJ, Marcello SR, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. Journal of the American College of Cardiology. 2004; 43: 1211\u20131216.","DOI":"10.1016\/j.jacc.2003.10.057"},{"key":"ref31","unstructured":"Food and Drug Administration. Guidance for Industry E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2005. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0 (Accessed: 8 November 2021)."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Levine J, Massumi A, Scheinman MM, Winkle RA. The intravenous amiodarone multi-center study group: Preliminary report. Journal of the American College of Cardiology. 1990; 15: A27.","DOI":"10.1016\/0735-1097(90)91830-N"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, et al. Randomized, Double-Blind Comparison of Intravenous Amiodarone and Bretylium in the Treatment of Patients with Recurrent, Hemodynamically Destabilizing Ventricular Tachycardia or Fibrillation. Circulation. 1995; 92: 3255\u20133263.","DOI":"10.1161\/01.CIR.92.11.3255"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, et al. Dose-Ranging Study of Intravenous Amiodarone in Patients with Life-Threatening Ventricular Tachyarrhythmias. Circulation. 1995; 92: 3264\u20133272.","DOI":"10.1161\/01.CIR.92.11.3264"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Somberg JC, Bailin SJ, Haffajee CI, Paladino WP, Kerin NZ, Bridges D, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. The American Journal of Cardiology. 2002; 90: 853\u2013859.","DOI":"10.1016\/S0002-9149(02)02707-8"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ortiz M, Mart\u00edn A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. European Heart Journal. 2017; 38: 1329\u20131335.","DOI":"10.1093\/eurheartj\/ehw230"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Lopera G, Curtis AB. Risk stratification for sudden cardiac death: current approaches and predictive value. Current Cardiology Reviews. 2009; 5: 56\u201364.","DOI":"10.2174\/157340309787048130"},{"key":"ref38","unstructured":"Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013; 15: 1070\u2013118."},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994; 344: 493\u2013498.","DOI":"10.1016\/S0140-6736(94)91895-3"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia. New England Journal of Medicine. 1995; 333: 77\u201382.","DOI":"10.1056\/NEJM199507133330201"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Latchamsetty R, Yokokawa M, Morady F, Kim HM, Mathew S, Tilz R, et al. Multicenter Outcomes for Catheter Ablation of Idiopathic Premature Ventricular Complexes. JACC: Clinical Electrophysiology. 2015; 1: 116\u2013123.","DOI":"10.1016\/j.jacep.2015.04.005"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Devore AD, Mentz RJ, Patel CB. Medical management of patients with continuous-flow left ventricular assist devices. Current Treatment Options in Cardiovascular Medicine. 2014; 16: 283.","DOI":"10.1007\/s11936-013-0283-0"},{"key":"ref43","unstructured":"Gopinathannair R, Dhawan R, Vijayakrishnan R, Roukoz H, Bhan A, Ravichandran A, Ahmed MM, Bhat G, Cowger J, Abdallah M, Sandesara CM, Trivedi J SM. Amiodarone use and outcomes in continuous flow LVAD patients, Cochrane Central Register of Controlled Trials; 2017."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"El-Sabawi B, Hull JV, Tun H, Vaidya AS, Rahman JE, Pandya K, et al. Comparison of Amiodarone and Beta Blockers to Suppress Tachyarrhythmias in Patients with Left Ventricular Assist Devices. The Journal of Heart and Lung Transplantation. 2019; 38: S46.","DOI":"10.1016\/j.healun.2019.01.098"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. Journal of the American College of Cardiology. 1989; 13: 442\u2013449.","DOI":"10.1016\/0735-1097(89)90525-1"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. New England Journal of Medicine. 1996; 335: 1933\u20131940.","DOI":"10.1056\/NEJM199612263352601"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine. 2002; 346: 877\u2013883.","DOI":"10.1056\/NEJMoa013474"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias. The New England Journal of Medicine. 1997; 337:1576\u20131583.","DOI":"10.1056\/NEJM199711273372202"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Kuck K, Cappato R, Siebels J, Ru\u0308ppel R. Randomized Comparison of Antiarrhythmic Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Cardiac Arrest. Circulation. 2000; 102: 748\u2013754.","DOI":"10.1161\/01.CIR.102.7.748"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Bertomeu-Gonz\u00e1lez V, Moreno-Arribas J, Castillo-Castillo J, Mart\u00ednez-Ferrer J, Vi\u00f1olas X, Rodr\u00edguez A, et al. Etiology and Programming Effects on Shock Efficacy in ICD Recipients. Pacing and Clinical Electrophysiology. 2016; 39: 73\u201380.","DOI":"10.1111\/pace.12765"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Proietti R, Labos C, Davis M, Thanassoulis G, Santangeli P, Russo V, et al. A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality. The Canadian Journal of Cardiology. 2015; 31: 270\u2013277.","DOI":"10.1016\/j.cjca.2014.11.023"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Greene HL. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. The American Journal of Cardiology. 1993; 72: 70F\u201374F.","DOI":"10.1016\/0002-9149(93)90966-G"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Satomi K, Kurita T, Takatsuki S, Yokoyama Y, Chinushi M, Tsuboi N, et al. Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias. Circulation Journal. 2006; 70: 977\u2013984.","DOI":"10.1253\/circj.70.977"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. Journal of the American Medical Association. 2006; 295: 165\u2013171.","DOI":"10.1001\/jama.295.2.165"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Lee CH, Nam G, Park H, Kim HY, Park K, Kim J, et al. Effects of Antiarrhythmic Drugs on Inappropriate Shocks in Patients with Implantable Cardioverter Defibrillators. Circulation Journal. 2008; 72: 102\u2013105.","DOI":"10.1253\/circj.72.102"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Kowey PR, Crijns HJGM, Aliot EM, Capucci A, Kulakowski P, Radzik D, et al. Efficacy and Safety of Celivarone, with Amiodarone as Calibrator, in Patients with an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. Circulation. 2011; 124: 2649\u20132660.","DOI":"10.1161\/CIRCULATIONAHA.111.072561"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Vergara P, Trevisi N, Ricco A, Petracca F, Baratto F, Cireddu M, et al. Late potentials abolition as an additional technique for reduction of arrhythmia recurrence in scar related ventricular tachycardia ablation. Journal of Cardiovascular Electrophysiology. 2012; 23: 621\u2013627.","DOI":"10.1111\/j.1540-8167.2011.02246.x"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin J, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. New England Journal of Medicine. 2016; 375: 111\u2013121.","DOI":"10.1056\/NEJMoa1513614"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. The New England Journal of Medicine. 1999; 341: 871\u2013878.","DOI":"10.1056\/NEJM199909163411203"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. The New England Journal of Medicine. 2002; 346: 884\u2013890.","DOI":"10.1056\/NEJMoa013029"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Sanfilippo F, Corredor C, Santonocito C, Panarello G, Arcadipane A, Ristagno G, et al. Amiodarone or lidocaine for cardiac arrest: a systematic review and meta-analysis. Resuscitation. 2016; 107: 31\u201337.","DOI":"10.1016\/j.resuscitation.2016.07.235"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Tagami T, Matsui H, Tanaka C, Kaneko J, Kuno M, Ishinokami S, et al. Amiodarone Compared with Lidocaine for out-of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study. Cardiovascular Drugs and Therapy. 2016; 30: 485\u2013491.","DOI":"10.1007\/s10557-016-6689-7"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Lott C, Truhl\u00e1\u0159 A, Alfonzo A, Barelli A, Gonz\u00e1lez-Salvado V, Hinkelbein J, et al. European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances. Resuscitation. 2021; 161: 152\u2013219.","DOI":"10.1016\/j.resuscitation.2021.02.011"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Chowdhury A, Fernandes B, Melhuish TM, White LD. Antiarrhythmics in Cardiac Arrest: a Systematic Review and Meta-Analysis. Heart Lung and Circulation. 2018; 27: 280\u2013290.","DOI":"10.1016\/j.hlc.2017.07.004"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Panchal AR, Berg KM, Kudenchuk PJ, Del Rios M, Hirsch KG, Link MS, et al. 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs during and Immediately after Cardiac Arrest: an Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2018; 138: e740\u2013e749.","DOI":"10.1161\/CIR.0000000000000613"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Soar J, B\u00f6ttiger BW, Carli P, Couper K, Deakin CD, Dj\u00e4rv T, et al. European Resuscitation Council Guidelines 2021: Adult advanced life support. Resuscitation. 2021; 161: 115\u2013151.","DOI":"10.1016\/j.resuscitation.2021.02.010"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, et al. Amiodarone, Lidocaine, or Placebo in out-of-Hospital Cardiac Arrest. New England Journal of Medicine. 2016; 374: 1711\u20131722.","DOI":"10.1056\/NEJMoa1514204"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Kudenchuk PJ, Leroux BG, Daya M, Rea T, Vaillancourt C, Morrison LJ, et al. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable out-of-Hospital Cardiac Arrest. Circulation. 2017; 136: 2119\u20132131.","DOI":"10.1161\/CIRCULATIONAHA.117.028624"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Tagami T, Yasunaga H, Yokota H. Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation. Critical Care. 2017; 21: 59.","DOI":"10.1186\/s13054-017-1639-8"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Ohlow M, Geller JC, Richter S, Farah A, M\u00fcller S, Fuhrmann JT, et al. Incidence and predictors of ventricular arrhythmias after ST-segment elevation myocardial infarction. The American Journal of Emergency Medicine. 2012; 30: 580\u2013586.","DOI":"10.1016\/j.ajem.2011.02.029"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Rahimi K, Watzlawek S, Thiele H, Secknus M-A, Hayerizadeh B-F, Niebauer J, et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. European Heart Journal. 2006; 27: 1706\u20131711.","DOI":"10.1093\/eurheartj\/ehl100"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018; 39: 119\u201377.","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013; 34: 2949\u20133003.","DOI":"10.1093\/eurheartj\/eht296"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Cardiac Arrhythmia Suppression Trial II Investigators*. Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial Infarction. New England Journal of Medicine. 1992; 327: 227\u2013233.","DOI":"10.1056\/NEJM199207233270403"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation. 1991; 84: 1543\u20131551.","DOI":"10.1161\/01.CIR.84.4.1543"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. Journal of the American College of Cardiology. 1992; 20: 1056\u20131062.","DOI":"10.1016\/0735-1097(92)90357-S"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). Journal of the American College of Cardiology. 1990; 16: 1711\u20131718.","DOI":"10.1016\/0735-1097(90)90324-I"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Hockings BE, George T, Mahrous F, Taylor RR, Hajar HA. Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. The American Journal of Cardiology. 1987; 60: 967\u2013970.","DOI":"10.1016\/0002-9149(87)90334-1"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Budaj A, Kokowicz P, Smielak-Korombel W, Kuch J, Krzemi\u0144ska-Paku\u00f8a M, Maciejewicz J, et al. Lack of effect of amiodarone on survival after extensive infarction. Polish Amiodarone Trial. Coronary Artery Disease. 1996; 7: 315\u2013319.","DOI":"10.1097\/00019501-199604000-00008"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997; 349: 667\u2013674.","DOI":"10.1016\/S0140-6736(96)09145-3"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Elizari M. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. European Heart Journal. 2000; 21: 198\u2013205.","DOI":"10.1053\/euhj.1999.1687"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"von Olshausen K, Schafer A, Mehmel HC, Schwarz F, Senges J, Kubler W. Ventricular arrhythmias in idiopathic dilated cardiomyopathy. British Journal of Cardiology. 1984; 51: 195\u2013201.","DOI":"10.1136\/hrt.51.2.195"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Braunschweig F, Boriani G, Bauer A, Hatala R, Herrmann-Lingen C, Kautzner J, et al. Management of patients receiving implantable cardiac defibrillator shocks: recommendations for acute and long-term patient management. Europace. 2010; 12: 1673\u20131690.","DOI":"10.1093\/europace\/euq316"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation .2018; 138: e272\u2013e391.","DOI":"10.1161\/CIR.0000000000000614"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia\u2013AMIOVIRT. Journal of the American College of Cardiology. 2003; 41: 1707\u20131712.","DOI":"10.1016\/S0735-1097(03)00297-3"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. British Heart Journal. 1985; 53: 412\u2013416.","DOI":"10.1136\/hrt.53.4.412"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart. 2007; 93: 708\u2013710.","DOI":"10.1136\/hrt.2006.099416"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Gao Y, Zhang P, Liang X. Effects of low-dose amiodarone and Betaloc on the treatment of hypertrophic cardiomyopathy complicated with malignant ventricular arrhythmias. Pakistan Journal of Medical Sciences. 2014; 30: 291\u2013294.","DOI":"10.12669\/pjms.302.4540"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Priori SG, Blomstr\u00f6m-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2015; 36: 2793\u20132867.","DOI":"10.1093\/eurheartj\/ehv316"},{"key":"ref90","unstructured":"Tonet J, Frank R, Fontaine G, Grosgogeat Y. Efficacy of the combination of low doses of beta-blockers and amiodarone in the treatment of refractory ventricular tachycardia. Archives des Maladies du C\u0153ur et des Vaisseaux. 1989; 82: 1511\u20131517. (In French)"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/4\/10.31083\/j.rcm2204143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:26:23Z","timestamp":1732728383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/4\/10.31083\/j.rcm2204143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"alternative-id":["S1530-6550(21)00243-X"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2204143","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,22]]},"article-number":"1383"}}